Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by mineoneon Oct 30, 2007 5:22pm
357 Views
Post# 13720364

Best part of release - mill news

Best part of release - mill newsPresident Michael Collins commented: "Bluerock is committed to developing shareholder value in the near term through toll milled production in Colorado, in the medium term with the development of resources and a mill in Utah, and in the long term, through the development of large minable resources through our Mongolian exploration. The acquisition of these five projects addresses our medium term goal to build sufficient uranium resources in Utah to support a 1200 ton per day Utah mill." figure the future earnings on a 1200 tpd mill. Big money. Historical grade at tramp was .28 to .32 % and at J Bird area was .34 Say .30% ave. x 1200 tpd x 2000# = 7200 # U a day 7200 x $80 x 365 = Gross $210 240 000 less costs of course and waste etc. Equals big future share price. I'm longer now more than ever. Mineone
Bullboard Posts